REWARDS Premier Taxus-Liberte vs Xience V
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Other: Observational
- Registration Number
- NCT02256527
- Lead Sponsor
- Medstar Health Research Institute
- Brief Summary
Multicenter, retrospective registry to collect baseline, clinical, procedural, in hospital and 9-12 month follow-up data to compare major adverse cardiac events in patients receiving Promus Premier drug eluting stent to data already collected from the REWARDS-TLX Registry in which patients received either the Taxus Liberte or XIENCE V drug eluting stent.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 917
Inclusion Criteria
- Patients 18 years of age or older
- Underwent PCI with Promus Premier (alone) DES
Exclusion Criteria
- Underwent PCI with a non-Promus Premier DES during the same index procedure
- Patients not taking, or unable to take, dual antiplatelet therapy (aspirin plus clopidogrel, prasugrel, or ticagrelor)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Promus Premier Observational observational data
- Primary Outcome Measures
Name Time Method Major adverse cardiac event 1 year composite of all-cause death, Q-wave myocardial infarction, and target vessel revascularization
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Washington Hospital Center
🇺🇸Washington, District of Columbia, United States